益佰制药
(600594)
| 流通市值：32.94亿 | | | 总市值：32.94亿 |
| 流通股本：7.92亿 | | | 总股本：7.92亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 572,646,100.11 | 2,820,561,015 | 2,136,834,252.04 | 1,479,701,367.04 |
| 营业收入 | 572,646,100.11 | 2,820,561,015 | 2,136,834,252.04 | 1,479,701,367.04 |
| 二、营业总成本 | 635,203,702.04 | 2,621,425,841.6 | 1,930,208,223.55 | 1,316,998,284.2 |
| 营业成本 | 225,763,334.16 | 861,096,285.77 | 627,805,844.57 | 425,615,160.01 |
| 税金及附加 | 9,499,480.87 | 42,658,654.5 | 33,943,469.9 | 23,135,621.51 |
| 销售费用 | 292,185,359.66 | 1,238,440,637.53 | 936,756,363.4 | 650,985,213.32 |
| 管理费用 | 76,890,947.91 | 351,478,112.98 | 246,765,695.89 | 166,309,814.06 |
| 研发费用 | 22,795,778.94 | 112,147,338 | 73,852,804.23 | 48,369,912.16 |
| 财务费用 | 8,068,800.5 | 15,604,812.82 | 11,084,045.56 | 2,582,563.14 |
| 其中:利息费用 | 9,611,697.66 | 21,642,251.59 | 14,392,620.02 | 4,793,313.2 |
| 其中:利息收入 | 2,054,991.81 | 7,070,673.2 | 4,793,286.54 | 3,181,445.77 |
| 加:投资收益 | 58,699.85 | 28,699.17 | 113,142.65 | 23,930.43 |
| 资产处置收益 | 89,603.73 | 16,639.11 | 16,639.11 | 16,639.11 |
| 资产减值损失(新) | -10,322,080.01 | -94,051,202.52 | -27,429,216.25 | -20,925,686.57 |
| 信用减值损失(新) | 45,716.78 | 3,696,796.49 | 1,003,915.2 | 973,208.72 |
| 其他收益 | 4,954,499.44 | 28,531,850.86 | 18,977,405.16 | 12,952,450.7 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -67,731,162.14 | 137,357,956.51 | 199,307,914.36 | 155,743,625.23 |
| 加:营业外收入 | 29,426.67 | 4,793,116.4 | 1,201,830.03 | 196,016.8 |
| 减:营业外支出 | 2,063,978.25 | 9,830,368.27 | 5,602,198.22 | 2,297,301.03 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -69,765,713.72 | 132,320,704.64 | 194,907,546.17 | 153,642,341 |
| 减:所得税费用 | 1,646,069.06 | 40,963,583.51 | 33,407,638.86 | 31,913,947.39 |
| 六、净利润 | -71,411,782.78 | 91,357,121.13 | 161,499,907.31 | 121,728,393.61 |
| 持续经营净利润 | -71,411,782.78 | 91,357,121.13 | 161,499,907.31 | 121,728,393.61 |
| 归属于母公司股东的净利润 | -68,454,808.45 | 103,399,049.91 | 169,869,961.21 | 127,906,049.29 |
| 少数股东损益 | -2,956,974.33 | -12,041,928.78 | -8,370,053.9 | -6,177,655.68 |
| (一)基本每股收益 | -0.09 | 0.13 | 0.22 | 0.16 |
| (二)稀释每股收益 | -0.09 | 0.13 | 0.22 | 0.16 |
| 八、其他综合收益 | 39,540.83 | -343,624.32 | -343,624.32 | - |
| 归属于母公司股东的其他综合收益 | 39,540.83 | -343,624.32 | -343,624.32 | - |
| 九、综合收益总额 | -71,372,241.95 | 91,013,496.81 | 161,156,282.99 | 121,728,393.61 |
| 归属于母公司股东的综合收益总额 | -68,415,267.62 | 103,055,425.59 | 169,526,336.89 | 127,906,049.29 |
| 归属于少数股东的综合收益总额 | -2,956,974.33 | -12,041,928.78 | -8,370,053.9 | -6,177,655.68 |
| 公告日期 | 2024-04-19 | 2024-04-19 | 2023-10-27 | 2023-08-18 |
| 审计意见(境内) | | 标准无保留意见 | | |